Carbon Biosciences
Yoshi Hashimoto has extensive experience in research and development within various biotechnology and pharmaceutical companies. Currently serving as the Director of Novel Vector Development and Platform Development at Carbon Biosciences, Hashimoto previously held roles such as Principal Scientist I at BioMarin Pharmaceutical Inc. and Principal Scientist at Sanofi. With a background in molecular biology, Hashimoto has contributed significantly to the field through projects such as the development of gene knockout baculovirus and the molecular characterization of fire ant viruses. With a PhD in Insect Virology from Nagoya University, Hashimoto's expertise spans across various aspects of gene therapy and virology research.
Carbon Biosciences
1 followers
Carbon Biosciences is expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues, carry a larger cargo, with minimal neutralizing immunity and the potential to re-dose. Founded by Longwood Fund and gene therapy pioneers John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D., Carbon is expanding the gene therapy toolbox for the treatment of the world’s most devastating and difficult to treat diseases.